Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach

Cision Canada

19 hours ago

HERZLIYA, Israel and CALGARY, AB, June 13, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries proudly announces the third party publication of a peer-reviewed narrative review in Cureus journal titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: https://doi.org/10.7759/cureus.81577). The article discusses the therapeutic potential of long-acting synthetic cannabidiol (CBD) in addressing chronic pain—an urgent global health challenge for which safer, more effective treatments are desperately needed.
Co-authored by leading pain specialists from institutions such as Johns Hopkins University and NYU School of Medicine, the review highlights that synthetic CBD administered through extended-release formulations could offer a well-tolerated, non-opioid analgesic alternative with the potential to significantly reduce reliance on addictive opioids.
Chronic pain affects over 24% of adults in the United States alone, placing a significant burden on patients, healthcare systems, and economies*. Yet, long-term treatment options remain inadequate. NSAIDs pose cumulative toxicity risks, and opioids—while effective—present serious concerns including tolerance, dependency, and overdose risk. Globally, opioid misuse results in over 100,000 deaths annually (DOI: 10.1016/j.lana.2023.100557).
The U.S. Food and Drug Administration (FDA) has emphasized the critical need for novel, non-addictive pain therapies through its "Guidance for Industry: Non-Opioid Analgesic Development Programs". Innocan's proprietary LPT-CBD platform is uniquely positioned to align with this regulatory focus. LPT-CBD is an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by various animal studies, LPT-CBD produces steady CBD plasma levels for up to four weeks, delivers prolonged pain relief, and is well tolerated, offering a promising alternative to current opioid medication and abuse.
Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials. This progress marks a pivotal step toward realizing a first-in-class, non-opioid analgesic therapy tailored for the complexities of chronic pain management.
"This publication underscores the urgent need for innovative, non-opioid analgesics that offer long-lasting efficacy," said Dr. Paul J. Christo, Associate Professor and Chief of the Division of Pain Medicine at the Johns Hopkins University School of Medicine and co-author of the article. "Liposomal synthetic CBD could offer a safe and scalable solution for a variety of painful conditions."
"Given the current addiction crisis, there is an immediate need to replace opioids with safer, effective alternatives," noted Dr. Eugene Vortsman, Clinical Director of Addiction Medicine and Disease Management at Northwell Health and co-author of the article. "Long-acting synthetic CBD has real potential to shift the paradigm."
Iris Bincovich, Chief Executive Officer of Innocan added:"We are thrilled by this breakthrough publication. Innocan is fully committed to advancing LPT-CBD toward clinical development, with the goal of delivering an innovative and safe non-opioid analgesic solution for chronic pain management."
Reference
Opioid crisis: addiction, overprescription, and insufficient primary prevention, The Lancet Regional Health – Americas 2023;23: 100557. DOI: 10.1016/j.lana.2023.100557
, Eugene Vortsman, Christopher Gharibo, Jo Ann K. LeQuang, Joseph V. Pergolizzi. Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review. Cureus Journal of Medical Science. DOI: 10.7759/cureus.81577
About Innocan:
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.
www.innocanpharma.com
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
[phone]
[phone]
[phone]
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.